



ISSN (E): 2277-7695  
ISSN (P): 2349-8242  
NAAS Rating: 5.23  
TPI 2023; SP-12(8): 1800-1807  
© 2023 TPI  
[www.thepharmajournal.com](http://www.thepharmajournal.com)  
Received: 08-06-2023  
Accepted: 20-07-2023

**Sarmistha Debbarma**  
M.V.Sc, Department of  
Veterinary Medicine, Ethics &  
Jurisprudence; West Bengal  
University of Animal & Fishery  
Sciences, Kolkata, West Bengal,  
India

**Nishith Ranjan Pradhan**  
Professor, Department of  
Veterinary Medicine, Ethics &  
Jurisprudence; West Bengal  
University of Animal & Fishery  
Sciences, Kolkata, West Bengal,  
India

**Debaki Ghosh**  
Professor, Department of  
Veterinary Surgery & Radiology;  
West Bengal University of  
Animal & Fishery Sciences,  
Kolkata-37, West Bengal, India

**Corresponding Author:**  
**Sarmistha Debbarma**  
M.V.Sc, Department of  
Veterinary Medicine, Ethics &  
Jurisprudence; West Bengal  
University of Animal & Fishery  
Sciences, Kolkata, West Bengal,  
India

## Comparative efficacy of Nemocid, Albomar and Alfanil in cases of spontaneous Toxocariasis at dog ward, teaching veterinary clinical complex, WBUAFS, Kolkata, West Bengal, India

**Sarmistha Debbarma, Nishith Ranjan Pradhan and Debaki Ghosh**

### Abstract

**Introduction:** Toxocariasis is a worldwide parasitic infection and dogs serve as the most important definitive hosts for *Toxocara canis*: a causative agent of human toxocariasis and one of the most widespread zoonotic helminths worldwide.

**Materials and methods:** For this study out of 24/42 positive pups irrespective of age, sex and breeds were randomly selected. Total 30 pups divided into 5 groups of 6 puppies as: Group 1: Healthy control, Group 2: Untreated control, Group 3: Nemocid (Pyrantel pamoate) suspension @50 mg/kg bw/d orally as single dose, Group 4: Albomar (Albendazole) suspension @50 mg/kg bw/d for 3 days orally and, Group 5: Alfanil tablet (combination of Praziquantel, Pyrantel embonate and Oxantel embonate) @1 tab/10 kg bw/d orally as single dose. Animals were under observation for 9-months from treatment dosing and tests for clinical, haematological, biochemical and faecal examinations.

**Results:** Overall incidence of *Toxocara canis* infection in and around Kolkata city was 38.18%, with higher incidence during the monsoon (64.29%), sex-wise in males (66.67%), incidence-wise in age group 1-3 months, breed-wise in non-descript puppies (61.90%), and a decrease of haematological and biochemical parameters was observed in the pre-treatment infected pups. All three anthelmintics were found effective against the *Toxocara spp.* infection in the pups.

**Conclusion:** Considering the best efficacy, the combination of Praziquantel, Pyrantel embonate and Oxantel embonate at a dose rate of 1 tab/10 kg b.wt. as single dose can suitably be recommended for treatment of toxocariasis in pups.

**Keywords:** toxocariosis, *Toxocara canis*, zoonosis, efficacy, incidence, prevalence

### 1. Introduction

The name "*Toxocara*" is derived from the Greek word "toxos," meaning bow or quiver, and the Latin word "caro," meaning flesh (Bassett and Thomas, 2014) <sup>[1]</sup>. Toxocariasis is a worldwide parasitic infection, primarily rendered by *Toxocara canis* in dogs, *Toxocara cati* in cats and foxes and *Toxascaris leonina* in a wide range of carnivores (Chen *et al.*, 2012) <sup>[2]</sup>. Dogs serve as the most important definitive hosts for *Toxocara canis*: a causative agent of human toxocariasis and one of the most widespread zoonotic helminths worldwide (Rostami *et al.*, 2020) <sup>[3]</sup>.

Toxocariasis in dogs is caused by ingestion of fully embryonated eggs or ingestion of infective larvae together with paratenic host of nematode roundworm *Toxocara canis* (Mondal and Basak, 2001) <sup>[4]</sup>. It is the most common *Toxocara* parasite of concern to humans, which puppies usually contract from their mother before birth or from her milk. In 3 to 4 weeks old pups, the larvae mature in the intestine and the worms start to produce large quantity of eggs which ultimately shed in to the environment through the faeces. Within 2 to 4 weeks the infective larvae can develop into eggs in the environment and the ingestion of these eggs can make one infected with toxocariasis (Centre for Disease Control, 2023) <sup>[5]</sup>. In an epidemiological perspective, animal hosts parasitized by adult worms in their gut can disseminate infection by shedding parasite eggs into environment (Eslahi *et al.*, 2020) <sup>[6]</sup>.

Epidemiological surveys have indicated that the prevalence of *Toxocara canis* in dogs ranged from 5.5% to 64.7% (Minnaar *et al.*, 2002; Oliveira-Sequeira *et al.*, 2002; Habluetzel *et al.*, 2003; Rubel *et al.*, 2003; Wang *et al.*, 2006; Dai *et al.*, 2009) <sup>[7-12]</sup>. Recent meta-analysis study has estimated overall prevalence of soil contamination with *Toxocara spp.* eggs in public places as 11.26% (95% CI 07.59–15.54%) across India (Bhargale *et al.*, 2021) <sup>[13]</sup>.

Toxocariasis due to several species of *Toxocara* and/or *Toxascaris* roundworms is still a seriously notifiable public health issue, particularly due to its intricate transmission routes (Eslahi *et al.*, 2020) [16].

Normally a normal sized dog lightly infected with *Toxocara canis* passes 136 gm of faeces per day having 10000 Eggs Per Gram of Faeces (EPGF) (Ahmad *et al.*, 2011) [14]. The estimation of EPGF is very simple yet effective method to predict the severity and parasitic burden of *Toxocara canis* in dogs (Shulaw, 2011) [15]. After administration of anthelmintics, a reduction has been noticed in the number of ova discharged in faeces and improvement in haemato-biochemical parameters and, the efficacy can be compared by relative decrease in EPGF and also relative improvement in haemato-biochemical parameters (Rao and Suryanarayana, 1995) [16].

## 2. Materials and Methods

### 2.1 Study design

For this study a total of 110 puppies aged 0-6 months, irrespective of sex, breed and size and brought to the Dog ward under Teaching Veterinary Clinical Complex (TVCC), Faculty of Veterinary and Animal Sciences under West Bengal University of Animal and Fishery Sciences, Kolkata, India were examined for spontaneous ascariasis infection by *Toxocara canis*.

Out of 110 pups tested, 42 were found to be positive for

ascariasis of which 24 number of pups were selected at random. Total 30 pups divided into 5 groups of 6 puppies each were divided as: Group 1: Healthy control, Group 2: Untreated control, Group 3: Nemocid (Pyrantel pamoate) suspension @50 mg/kg bw/d orally as single dose, Group 4: Albomar (Albendazole) suspension @50 mg/kg bw/d for 3 days orally and, Group 5: Alfanil tablet (combination of Praziquantel, Pyrantel embonate and Oxantel embonate) @1 tab/10 kg bw/d orally as single dose. Animals under study group (n = 30) were under observation for 9-months from treatment dosing and tests for clinical, haematological, biochemical and faecal examinations were carried out once a month. The study was carried with approval of Institutional Animal Ethics Committee, West Bengal University of Animal and Fishery Sciences, Kolkata-37, India.

### 2.2 Prevalence of Toxocariosis

Faecal samples were collected from different portions of faecal volume. The samples were kept in individually marked vials and no preservative was added. For qualitative examination, samples were examined by direct smear method and centrifugation technique, and quantitatively by modified Mc. Master's Technique (Soulsby, 1982) [17] for determining the eggs per gram (EPG) of faeces. Incidence was calculated based on observations specific to breed, age, sex and season and overall incidence of *Toxocara spp.* infection in pups was calculated as:

$$\text{Overall incidence of Toxocara spp.} = \frac{\text{No. of positive samples for Toxocara spp.}}{\text{Total no. of samples}} \times 100$$

### 2.3 Haemato-biochemical analysis

**2.3.1 Blood sample collection and processing:** The blood samples were collected from all the group of pups on 0th, 7<sup>th</sup>, 15<sup>th</sup> and 30<sup>th</sup> days for the haematological and biochemical studies. About 7 mL of blood was collected aseptically from the cephalic or saphenous veins with a sterile 10 mL disposable syringe from each animal. Out of 7 mL, 1 mL was transferred from the syringe to the vials containing EDTA for estimation of Haemoglobin (Hb), Differential Leukocytic Count (DLC), Total Erythrocytic Count (TEC) and Total Leukocytic Count (TLC). 4 mL of blood was allowed to clot to collect serum and stored at -20° C after proper levelling for biochemical investigations. Another 2 mL of blood was transferred to the serum vials containing heparin for estimation of Glucose.

**2.3.2 Estimation of haematological parameters:** Hb (g/dL) was estimated by Sahli's method (Schalm *et al.*, 1975) [18]. TEC ( $\times 10^6/\mu\text{L}$ ) and TLC ( $\times 10^3/\mu\text{L}$ ) of blood was estimated by the Haemocytometer. DLC (%) was estimated by hematocrit tube method and blood films stained by Giemsa staining method (Schalm *et al.*, 1975) [18].

**2.3.3 Estimation of serum biochemical parameters:** TSP (g/dL) was estimated spectrophotometrically by Modified Biuret End Point Assay methods (Koller, 1984) [19]. Serum albumin (g/dL) was estimated spectrophotometrically by Bromocresol Green End Point Assay method (Corcoran and Durran, 1977) [20] and serum globulin (g/dL) was calculated by subtracting the serum albumin value from the total serum protein values. The blood glucose level (mg/dL) was estimated spectrophotometrically by GOD-POD based end-point method (Tietz, 1976) [21]. Serum AST (IU/L) and serum

ALT (IU/L) values were estimated spectrophotometrically by 2,4- DNP method (Reitman and Frankel, 1957) [22]. Total serum bilirubin was estimated spectrophotometrically by Malloy and Evelyn Method (Malloy and Evelyn, 1937) [23] and Serum creatinine level was estimated spectrophotometrically by Alkaline Picrate method (Toro and Ackermann, 1975) [24]. All estimations were carried out by using commercial kits supplied by Span Diagnostic Ltd., Surat, India.

**2.4 Therapeutic trail:** Therapeutic trial was conducted to evaluate the efficacy of three different anthelmintic drugs for treatment of the naturally infected *Toxocara spp.* infection in pups in different groups to evaluate their efficacies. For assessing the reduction of EPG count, the faecal samples were collected on day '0' before treatment and subsequently on 3<sup>rd</sup>, 7<sup>th</sup>, 14<sup>th</sup> and 28<sup>th</sup> days of post medication. The percent efficacy was done as follows (Soulsby, 1994) [25]:

$$\text{Efficacy \%} = \frac{\text{EPG before treatment} - \text{EPG after treatment}}{\text{EPG before treatment}} \times 100$$

**2.5 Statistical analysis:** Data obtained under present investigation were entered in spreadsheet for descriptive analysis (mean and percent) and SPSS version 10.0 was used for ANOVA (Snedecor and Cochran, 1976) [26].

## 3. Results and Discussion

### 3.1 Incidence

Overall incidence of *Toxocara spp.* infection in pups in this study was found 38.18% and this finding corroborates with the findings of Negrea (2005) [27] who also reported that, other than transplacental infection, puppies are mostly infected from the mother's faeces.

$$\text{Overall incidence of Toxocara spp.} = \frac{42}{110} \times 100 = 38.18\%$$

Higher incidences of *Toxocara canis* infection was recorded in males (66.67%), monsoon season (64.29%), age group of 1-3 months (54.77%), and amongst the non-descript pups (61.90%) [Table 1]. Season wise incidence might be due to effect of rainfall in the translocation and acquisition of L3 infective larvae in the environment as referred to by Soulsby (1994) [25].

**3.2 Haematological parameters:** The results of the haematological observations in different groups of pups have been presented in Table 2 and Figure 1. Hb levels of the infected pups of Groups 2, 3 4 and 5 were significantly

( $p < 0.01$ ) lower than Group 1 on 0<sup>th</sup> day simulated with the observations of Chattha *et al.* (2009) [28] in pups with toxocarosis which might be due to extensive tissue damage of the intestinal wall and blood sucking behaviour of the infective larvae of *Toxocara spp.* in puppies as also opined by Deger *et al.* (1997) [29]. The TEC of the infected puppies of Groups 2, 3, 4 & 5 also showed significant ( $p < 0.01$ ) declination on 0<sup>th</sup> day than Group 1, but following treatment in Groups 3,4 & 5, the values improved markedly on 30<sup>th</sup> day. The TLC of the infected puppies (Groups 2, 3, 4 & 5) increased significantly ( $p < 0.01$ ) on 0<sup>th</sup> day than the healthy control puppies (Gr.1) indicating marked leucocytosis and are in conformity with Sharma *et al.* (2010) [33] who also noted increased TLC with toxocarosis in pups.

**Table 1:** Distribution of positive samples of *Toxocara canis* in pups

Age-wise incidence			Breed-wise incidence			Season-wise incidence		
Age	Cases	Incidence	Breed	Cases	Incidence	Season	Cases	Incidence
1-3 months	23	54.77%	Labrador	1	2.38%	Winter (Dec-Feb)	4	9.52%
4-6 months	19	45.23%	German Spitz	4	9.52%	Summer (Mar-May)	11	26.19%
Sex-wise incidence			German Shepherd	1	2.38%	Monsoon (Jun-Aug)	27	64.29%
Sex	Cases	Incidence	Golden Retriever	1	2.38%	Total samples	Positive samples	Negative samples
Male	28	66.67%	Cross-breed	9	21.44%	110	42	68
Female	16	33.33%	Non-descript	26	61.90%	Overall Incidence		38.18%

There was a significant ( $p < 0.01$ ) elevation of Neutrophil percentages in Groups 2, 3, 4 & 5 than the Group 1 puppies and simulated with the observations of Sharma *et al.* (2010) [33]. There was further increase of the values in Group 2 puppies, while declinations were noted in Groups 3, 4 & 5. In treatment groups, a significant improvement ( $p < 0.01$ ) in lymphocyte percentage observed in Group 3 on 30<sup>th</sup> day, and on 15<sup>th</sup> day in Group 4 and Group 5. This improvement in lymphocytic percentages indicated the control of secondary bacterial infections in toxocarosis.

The eosinophil levels were significantly higher ( $p < 0.01$ ) in Groups 2, 3, 4 and 5 compared to the Group 1 healthy control on 0<sup>th</sup> day and is in agreement with the observations of

Chatterjee *et al.* (1993) [31], Ogunkoya *et al.* (2006) [32], Sharma *et al.* (2010) [33] and Devi *et al.* (2011) [34], who also noted eosinophilia in *Toxocara* infections. Chatterjee *et al.* (1993) [31] opined that eosinophilia could be due to the pro-inflammatory process and tissue injuries triggered following larval migration and subsequent release of histamine or serotonin like chemo attractants in dogs. The monocyte levels of the healthy pups in Group 1 corroborates with the observations of Coles (1986) [35], and a decrease level of monocytes on 0<sup>th</sup> day corroborates with the findings of Sharma *et al.* (2010) [33] who observed a decrease in monocyte levels in experimentally infected chickens with *Toxocara spp.*

**Table 2:** Haematological changes in control and treatment groups of pups

Sl. No.	Parameter	Group	Pre-treatment	Days of observation post-treatment		
			0 <sup>th</sup> Day	7 <sup>th</sup> Day	15 <sup>th</sup> Day	30 <sup>th</sup> Day
1	Hb (g/dL)	I	13.89±0.10 <sup>a</sup>	13.93±0.11 <sup>a</sup>	13.95±0.10 <sup>a</sup>	13.96±0.10 <sup>a</sup>
		II	9.18±0.08 <sup>d<sub>w</sub></sup>	9.02±0.05 <sup>e<sub>wx</sub></sup>	8.87±0.06 <sup>d<sub>xy</sub></sup>	8.77±0.05 <sup>d<sub>y</sub></sup>
		III	9.40±0.03 <sup>cd<sub>z</sub></sup>	9.69±0.02 <sup>d<sub>y</sub></sup>	10.35±0.11 <sup>c<sub>x</sub></sup>	11.25±0.03 <sup>bc<sub>w</sub></sup>
		IV	9.74±0.06 <sup>b<sub>y</sub></sup>	10.35±0.05 <sup>b<sub>x</sub></sup>	11.02±0.04 <sup>b<sub>w</sub></sup>	11.19±0.06 <sup>c<sub>w</sub></sup>
		V	9.54±0.03 <sup>bc<sub>z</sub></sup>	9.96±0.04 <sup>c<sub>y</sub></sup>	10.51±0.04 <sup>c<sub>x</sub></sup>	11.48±0.04 <sup>b<sub>w</sub></sup>
2	TEC (x10 <sup>6</sup> /μL)	I	7.02±0.02 <sup>a<sub>y</sub></sup>	7.05±0.01 <sup>a<sub>xy</sub></sup>	7.08±0.01 <sup>a<sub>wx</sub></sup>	7.12±0.01 <sup>a<sub>w</sub></sup>
		II	5.07±0.04 <sup>b<sub>w</sub></sup>	4.85±0.03 <sup>b<sub>x</sub></sup>	4.77±0.02 <sup>c<sub>xy</sub></sup>	4.73±0.02 <sup>d<sub>y</sub></sup>
		III	4.82±0.03 <sup>c<sub>x</sub></sup>	4.89±0.02 <sup>b<sub>x</sub></sup>	4.94±0.04 <sup>b<sub>x</sub></sup>	5.18±0.02 <sup>b<sub>w</sub></sup>
		IV	4.60±0.02 <sup>d<sub>z</sub></sup>	4.70±0.01 <sup>c<sub>y</sub></sup>	4.83±0.01 <sup>c<sub>x</sub></sup>	4.74±0.02 <sup>c<sub>w</sub></sup>
		V	4.44±0.01 <sup>c<sub>z</sub></sup>	4.56±0.02 <sup>d<sub>y</sub></sup>	4.74±0.02 <sup>c<sub>x</sub></sup>	5.11±0.02 <sup>b<sub>w</sub></sup>
3	TLC (x10 <sup>3</sup> /μL)	I	11.39±0.07 <sup>b</sup>	11.47±0.08 <sup>b</sup>	11.54±0.07 <sup>c</sup>	11.63±0.08 <sup>cd</sup>
		II	14.35±0.30 <sup>a</sup>	14.47±0.29 <sup>a</sup>	14.57±0.30 <sup>ab</sup>	14.67±0.30 <sup>a</sup>
		III	13.78±0.33 <sup>a</sup>	13.63±0.32 <sup>a</sup>	13.42±0.33 <sup>ab</sup>	13.22±0.33 <sup>b</sup>
		IV	14.31±0.43 <sup>a</sup>	14.08±0.43 <sup>a</sup>	13.78±0.42 <sup>ab</sup>	13.13±0.35 <sup>ab</sup>
		V	13.97±0.33 <sup>a</sup>	13.65±0.34 <sup>a</sup>	13.13±0.35 <sup>b</sup>	12.69±0.35 <sup>bc</sup>
4	Neutrophil (%)	I	70.58±0.20 <sup>b<sub>x</sub></sup>	71.66±0.21 <sup>b<sub>w</sub></sup>	70.17±0.17 <sup>c<sub>xy</sub></sup>	69.50±0.22 <sup>c<sub>y</sub></sup>
		II	73.83±0.30 <sup>a<sub>x</sub></sup>	74.66±0.42 <sup>a<sub>wx</sub></sup>	75.50±0.42 <sup>a<sub>wx</sub></sup>	76.167±0.60 <sup>a<sub>w</sub></sup>
		III	74.00±0.57 <sup>a</sup>	73.66±0.61 <sup>ab</sup>	72.83±0.61 <sup>b</sup>	71.83±0.54 <sup>b</sup>
		IV	74.33±0.61 <sup>a<sub>w</sub></sup>	73.17±0.65 <sup>ab<sub>wx</sub></sup>	72.00±0.65 <sup>bc<sub>x</sub></sup>	68.67±0.21 <sup>c<sub>y</sub></sup>
		V	75.00±0.68 <sup>a<sub>w</sub></sup>	73.17±0.75 <sup>ab<sub>wx</sub></sup>	71.17±0.75 <sup>bc<sub>x</sub></sup>	68.17±0.54 <sup>c<sub>y</sub></sup>
5	Lymphocyte (%)	I	23.08±0.27 <sup>a<sub>xy</sub></sup>	22.33±0.21 <sup>a<sub>y</sub></sup>	23.83±0.31 <sup>a<sub>wx</sub></sup>	24.16±0.16 <sup>a<sub>w</sub></sup>
		II	18.33±0.56 <sup>b</sup>	17.66±0.61 <sup>b</sup>	17.16±0.60 <sup>d</sup>	16.83±0.40 <sup>c</sup>
		III	17.50±0.56 <sup>b<sub>x</sub></sup>	18.33±0.42 <sup>b<sub>wx</sub></sup>	19.00±0.26 <sup>cd<sub>wx</sub></sup>	19.67±0.21 <sup>b<sub>w</sub></sup>

		IV	17.66±0.49 <sup>b<sub>y</sub></sup>	18.83±0.31 <sup>b<sub>y</sub></sup>	20.50±0.50 <sup>bc<sub>x</sub></sup>	24.33±0.33 <sup>a<sub>w</sub></sup>
		V	17.33±0.76 <sup>b<sub>x</sub></sup>	19.33±0.61 <sup>b<sub>x</sub></sup>	22.00±0.61 <sup>ab<sub>w</sub></sup>	24.33±0.56 <sup>a<sub>w</sub></sup>
6	Eosinophil (%)	I	3.00±0.00 <sup>b<sub>w</sub></sup>	2.83±0.01 <sup>b<sub>w</sub></sup>	2.66±0.21 <sup>c<sub>wx</sub></sup>	3.00±0.00 <sup>b<sub>w</sub></sup>
		II	5.16±0.54 <sup>a</sup>	5.50±0.61 <sup>a</sup>	5.16±0.60 <sup>a</sup>	5.66±0.49 <sup>a</sup>
		III	5.66±0.42 <sup>a<sub>w</sub></sup>	5.00±0.51 <sup>a<sub>wx</sub></sup>	4.66±0.33 <sup>ab<sub>wx</sub></sup>	3.83±0.16 <sup>b<sub>x</sub></sup>
		IV	5.33±0.49 <sup>a<sub>w</sub></sup>	4.66±0.21 <sup>a<sub>wx</sub></sup>	3.66±0.21 <sup>bc<sub>xy</sub></sup>	3.16±0.30 <sup>b<sub>y</sub></sup>
		V	5.66±0.42 <sup>a<sub>w</sub></sup>	4.50±0.22 <sup>a<sub>x</sub></sup>	3.66±0.21 <sup>bc<sub>xy</sub></sup>	3.00±0.00 <sup>b<sub>y</sub></sup>
7	Monocyte (%)	I	3.33±0.21 <sup>a</sup>	3.16±0.17	3.33±0.21 <sup>a</sup>	3.33±0.21 <sup>c</sup>
		II	2.67±0.21 <sup>ab<sub>y</sub></sup>	2.16±0.17 <sub>w</sub>	2.17±0.16 <sup>b<sub>w</sub></sup>	1.33 ±0.21 <sup>d<sub>x</sub></sup>
		III	2.83±0.17 <sup>ab<sub>x</sub></sup>	3.00 ±0.36 <sub>x</sub>	3.50±0.22 <sup>a<sub>x</sub></sup>	4.67±0.21 <sup>a<sub>w</sub></sup>
		IV	2.67±0.21 <sup>ab<sub>x</sub></sup>	3.33±0.33 <sub>wx</sub>	3.83±0.16 <sup>a<sub>w</sub></sup>	3.67±0.21 <sup>bc<sub>w</sub></sup>
		V	2.00±0.25 <sup>ab<sub>y</sub></sup>	3.00 ± 0.36 <sub>xy</sub>	3.17±0.31 <sup>a<sub>x</sub></sup>	4.50±0.22 <sup>ab<sub>w</sub></sup>

Mean bearing different superscripts (a, b, c, d and e) in a column differ significantly (*p*<0.01).

Mean bearing different subscripts (w, x, y and z) in a row differ significantly (*p*<0.01).



**Fig 1:** Haematological changes in control and treatment groups of pups

**3.3 Serum biochemical parameters:** The results of the haematological observations in different groups of pups have been presented in Table 3 and Figure 2. The table shows that there were significantly ( $p<0.01$ ) lower levels of total serum protein on 0<sup>th</sup> day in Groups 2, 3, 4 & 5 in comparison to the healthy control puppies of Group 1. These findings are in conformity with Brar *et al.* (1993) [36] with toxocarosis and it might be due to impaired absorption of nutrients from the intestine and poor intake of food. In Group 2, there was further decrease of the values while in Groups 3, 4 & 5, the TSP values increased markedly at the end and best improvement was noted in Group 5.

The blood glucose values of the infected pups of Groups 2, 3, 4 & 5 was significantly ( $p<0.01$ ) low on 0<sup>th</sup> day than the puppies of Groups 1 and agrees with the observations of Brar *et al.* (1993) [36] and it might be due to impaired absorption of nutrients in the intestine following *Toxocara spp.* infection. But with anthelmintic treatments in Groups 3, 4 & 5, the blood glucose levels increased significantly ( $p<0.01$ ) at the end of the experiment when there was still further deterioration in Group 2.

The serum bilirubin levels in Groups 2, 3, 4 & 5 increased moderately on 0<sup>th</sup> day than the healthy pups of Group 1 and in agreement with the findings of Mondal *et al.* (2001) [4] who also noted mild increase of bilirubin levels in pups with toxocarosis and opined *Toxocara spp.* infection produces hepatic insufficiency and increases the serum bilirubin levels. However, following therapy with anthelmintics along, the values gradually improved in different treated groups. The

mean values of AST in Groups 2, 3, 4 & 5 were significantly high ( $p<0.01$ ) on 0<sup>th</sup> day in comparison to Group 1 and simulated with the observations of Mondal *et al.* (2001) [4] who also recorded higher AST values in piglets with *Toxocara spp.* infection and it might be due to hepatic insufficiency. But following treatment in Groups 3, 4 and 5, the AST values declined significantly ( $p<0.01$ ) and became almost normal at the end of the experiment. Similarly, the ALT values were also found significantly high ( $p<0.01$ ) on 0<sup>th</sup> day in the infected groups (Groups 2, 3, 4 and 5) and confirmed the findings of Mondal *et al.*, 2001 [4] in piglets with toxocarosis. However, in the treated groups (Groups 3, 4 & 5) the values almost became normal on 30<sup>th</sup> day, while it still remained significantly ( $p<0.01$ ) elevated in Group 2.

Significantly lower levels of serum globulin were observed in Groups 2, 3, 4 and 5 on 0<sup>th</sup> day and it simulated with the findings of Rao *et al.* (1995) [16] who also noted decreased globulin levels in *Toxocara canis* infected pups and dogs, respectively. Following treatment in Groups 2, 3, 4 and 5, The mean albumin values were significantly lower ( $p<0.01$ ) in all infected groups on 0<sup>th</sup> day and simulated with the observations of Rao *et al.* (1995) [16] who noted a decrease in serum albumin levels in dogs with *Toxocara canis* infection, which might be due to declination of diet intake, malabsorption and protein losing enteropathy owing to toxocarosis. However, following treatments in Groups 3, 4, and 5, the total serum albumin values became normal at the end of the experiment indicating control of *Toxocara* infection in these pups.


**Table 3:** Biochemical changes in control and treatment groups of pups

Sl. No.	Parameter	Group	Pre-treatment	Days of observation post-treatment		
			0 <sup>th</sup> Day	7 <sup>th</sup> Day	15 <sup>th</sup> Day	30 <sup>th</sup> Day
1	Total Serum Protein (g/dL)	I	6.96±0.05 <sup>a</sup>	7.01±0.03 <sup>a</sup>	6.98±0.03 <sup>a</sup>	7.03±0.02 <sup>a</sup>
		II	4.90±0.09 <sup>c<sub>w</sub></sup>	4.90±0.09 <sup>c<sub>w</sub></sup>	4.58±0.07 <sup>d<sub>wx</sub></sup>	4.43±0.07 <sup>d<sub>x</sub></sup>
		III	5.20±0.05 <sup>b<sub>y</sub></sup>	5.33±0.05 <sup>b<sub>xy</sub></sup>	5.56±0.06 <sup>c<sub>wx</sub></sup>	5.76±0.06 <sup>c<sub>w</sub></sup>
		IV	4.95±0.04 <sup>c<sub>y</sub></sup>	5.26±0.04 <sup>b<sub>xy</sub></sup>	5.53±0.09 <sup>c<sub>w</sub></sup>	5.98±0.13 <sup>bc<sub>w</sub></sup>
		V	4.93±0.04 <sup>c<sub>y</sub></sup>	5.28±0.09 <sup>b<sub>x</sub></sup>	6.05±0.05 <sup>b<sub>x</sub></sup>	6.20±0.03 <sup>b<sub>w</sub></sup>
2	Serum Albumin (g/dL)	I	3.63±0.04 <sup>a</sup>	3.61 ± 0.06 <sup>a</sup>	3.50±0.05 <sup>a</sup>	3.56±0.05 <sup>a</sup>
		II	2.28±0.06 <sup>b<sub>w</sub></sup>	2.16 ± 0.05 <sup>d<sub>wx</sub></sup>	2.10±0.03 <sup>d<sub>x</sub></sup>	2.05±0.02 <sup>d<sub>x</sub></sup>
		III	2.35±0.03 <sup>b<sub>y</sub></sup>	2.45 ± 0.03 <sup>c<sub>y</sub></sup>	2.73±0.04 <sup>c<sub>x</sub></sup>	2.95±0.05 <sup>c<sub>w</sub></sup>
		IV	2.38±0.04 <sup>b<sub>z</sub></sup>	2.63±0.033 <sup>bc<sub>y</sub></sup>	2.86±0.03 <sup>c<sub>x</sub></sup>	3.01±0.03 <sup>c<sub>w</sub></sup>
		V	2.35±0.08 <sup>b<sub>y</sub></sup>	2.78±0.06 <sup>b<sub>x</sub></sup>	3.15±0.04 <sup>b<sub>w</sub></sup>	3.28±0.03 <sup>b<sub>w</sub></sup>
3	Serum Globulin (g/dL)	I	3.33±0.03 <sup>a</sup>	3.40±0.04 <sup>a</sup>	3.45±0.04 <sup>a</sup>	3.46±0.06 <sup>a</sup>
		II	2.61±0.09 <sup>c</sup>	2.56±0.06 <sup>c</sup>	2.48±0.06 <sup>c</sup>	2.40±0.07 <sup>c</sup>
		III	2.85±0.03 <sup>b</sup>	2.88±0.04 <sup>b</sup>	2.83±0.04 <sup>b</sup>	2.81±0.03 <sup>b</sup>
		IV	2.56±0.04 <sup>c<sub>x</sub></sup>	2.63±0.02 <sup>c<sub>x</sub></sup>	2.66±0.08 <sup>bc<sub>x</sub></sup>	2.96±0.10 <sup>b<sub>w</sub></sup>
		V	2.58±0.04 <sup>c<sub>x</sub></sup>	2.50±0.05 <sup>c<sub>x</sub></sup>	2.90±0.03 <sup>b<sub>w</sub></sup>	2.91±0.03 <sup>b<sub>w</sub></sup>
4	Albumin:Globulin ratio	I	1.08±0.02 <sup>a</sup>	1.06±0.03 <sup>ab</sup>	1.02±0.02 <sup>ab</sup>	1.03±0.03 <sup>a</sup>
		II	0.88±0.04 <sup>b</sup>	0.84±0.02 <sup>c</sup>	0.85±0.03 <sup>c</sup>	0.85±0.03 <sup>b</sup>
		III	0.83±0.02 <sup>b<sub>y</sub></sup>	0.85±0.02 <sup>c<sub>y</sub></sup>	0.97±0.03 <sup>b<sub>x</sub></sup>	1.04±0.02 <sup>a<sub>w</sub></sup>
		IV	0.93±0.03 <sup>b<sub>y</sub></sup>	0.99±0.01 <sup>b<sub>wx</sub></sup>	1.08±0.03 <sup>a<sub>w</sub></sup>	1.02±0.03 <sup>a<sub>wx</sub></sup>
		V	0.91±0.04 <sup>b<sub>x</sub></sup>	1.11±0.03 <sup>a<sub>w</sub></sup>	1.08±0.02 <sup>a<sub>w</sub></sup>	1.13±0.02 <sup>a<sub>w</sub></sup>
5	Blood Glucose(mg/dL)	I	105.00±2.04 <sup>a</sup>	105.50±1.78 <sup>a</sup>	105.66±2.02 <sup>a</sup>	106.33±2.01 <sup>ab</sup>
		II	69.00±0.51 <sup>b<sub>w</sub></sup>	67.50±0.50 <sup>d<sub>wx</sub></sup>	65.83±0.70 <sup>xy</sup>	64.33±0.55 <sup>c<sub>y</sub></sup>
		III	69.00±0.36 <sup>b<sub>z</sub></sup>	74.66±0.61 <sup>c<sub>y</sub></sup>	87.00±1.34 <sup>b<sub>x</sub></sup>	102.50±1.62 <sup>b<sub>w</sub></sup>
		IV	67.33±0.88 <sup>b<sub>z</sub></sup>	76.83±1.16 <sup>c<sub>y</sub></sup>	85.50±0.99 <sup>b<sub>w</sub></sup>	104.50±1.66 <sup>ab<sub>w</sub></sup>
		V	67.50±1.38 <sup>b<sub>y</sub></sup>	84.33±1.38 <sup>b<sub>x</sub></sup>	105.66±1.76 <sup>a<sub>w</sub></sup>	109.33±0.98 <sup>a<sub>w</sub></sup>
6	Serum Bilirubin(mg/dl)	I	0.38±0.02	0.40±0.00 <sup>b</sup>	0.38±0.01 <sup>b</sup>	0.40±0.00
		II	0.43±0.03	0.45±0.02 <sup>ab</sup>	0.45±0.02 <sup>ab</sup>	0.46±0.02
		III	0.43±0.02	0.41±0.01 <sup>ab</sup>	0.48±0.02 <sup>a</sup>	0.46±0.02
		IV	0.45±0.02	0.43±0.02 <sup>ab</sup>	0.42±0.02 <sup>ab</sup>	0.46±0.02
		V	0.46±0.02 <sup>w</sup>	0.48±0.02 <sup>a<sub>w</sub></sup>	0.48±0.02 <sup>a<sub>w</sub></sup>	0.40±0.00 <sub>x</sub>
7	AST (IU/L)	I	22.50±0.67 <sup>b</sup>	23.00±0.44 <sup>c</sup>	23.33±0.61 <sup>c</sup>	22.83±0.70 <sup>c</sup>
		II	42.66±1.70 <sup>a</sup>	43.83±1.64 <sup>a</sup>	45.16±1.60 <sup>a</sup>	45.83±1.57 <sup>a</sup>
		III	41.83±2.67 <sup>a<sub>w</sub></sup>	36.33±1.83 <sup>b<sub>wx</sub></sup>	31.33±1.08 <sup>b<sub>xy</sub></sup>	26.83±0.60 <sup>b<sub>y</sub></sup>

		IV	43.50±1.78 <sup>a</sup> <sub>w</sub>	36.50±1.20 <sup>b</sup> <sub>x</sub>	32.50±1.23 <sup>b</sup> <sub>x</sub>	26.66±0.80 <sup>bc</sup> <sub>y</sub>
		V	47.00±0.89 <sup>a</sup> <sub>w</sub>	36.33±1.42 <sup>b</sup> <sub>x</sub>	30.66±1.58 <sup>b</sup> <sub>y</sub>	24.33±0.76 <sup>bc</sup> <sub>z</sub>
8	ALT (IU/L)	I	31.33±1.08 <sup>b</sup>	32.33±0.84 <sup>d</sup>	32.83±0.40 <sup>c</sup>	33.50±0.42 <sup>bc</sup>
		II	66.16±2.98 <sup>a</sup>	67.83±2.91 <sup>a</sup>	68.33±3.14 <sup>a</sup>	69.50±3.04 <sup>a</sup>
		III	66.33±1.20 <sup>a</sup> <sub>w</sub>	58.50±1.54 <sup>b</sup> <sub>x</sub>	50.66±1.11 <sup>b</sup> <sub>y</sub>	39.33±1.96 <sup>b</sup> <sub>z</sub>
		IV	63.50±0.99 <sup>a</sup> <sub>w</sub>	55.16±0.79 <sup>bc</sup> <sub>x</sub>	47.16±1.16 <sup>b</sup> <sub>y</sub>	35.66±1.42 <sup>bc</sup> <sub>z</sub>
		V	68.83±1.66 <sup>a</sup> <sub>w</sub>	48.83±2.45 <sup>c</sup> <sub>x</sub>	38.00±1.39 <sup>c</sup> <sub>y</sub>	30.50±1.68 <sup>c</sup> <sub>z</sub>
9	Creatinine (mg/dL)	I	0.98±0.07 <sup>ab</sup>	0.98±0.09 <sup>b</sup>	0.98±0.10 <sup>bc</sup>	1.05±0.11 <sup>b</sup>
		II	1.33±0.05 <sup>b</sup> <sub>x</sub>	1.21±0.060 <sup>ab</sup> <sub>wx</sub>	1.35±0.04 <sup>a</sup> <sub>w</sub>	1.40±0.03 <sup>a</sup> <sub>w</sub>
		III	1.45±0.04 <sup>a</sup> <sub>w</sub>	1.31±0.04 <sup>a</sup> <sub>wx</sub>	1.26±0.06 <sup>a</sup> <sub>wx</sub>	1.18±0.06 <sup>ab</sup> <sub>wx</sub>
		IV	1.41±0.05 <sup>a</sup> <sub>w</sub>	1.33±0.04 <sup>a</sup> <sub>wx</sub>	1.23±0.04 <sup>ab</sup> <sub>x</sub>	1.05±0.04 <sup>b</sup> <sub>y</sub>
		V	1.43±0.07 <sup>a</sup> <sub>w</sub>	1.25±0.03 <sup>a</sup> <sub>wx</sub>	0.93±0.03 <sup>c</sup> <sub>x</sub>	0.90±0.05 <sup>c</sup> <sub>y</sub>

Mean bearing different superscripts (a, b, c, d and e) in a column differ significantly ( $p < 0.01$ ).

Mean bearing different subscripts (w, x, y and z) in a row differ significantly ( $p < 0.01$ ).



**Fig 2:** Biochemical changes in control and treatment groups of pups

The serum creatinine values of the healthy control pups of Group 1 varied from 0.98±0.07 mg/dL to 1.05±0.11 mg/dL during the entire experiment, and simulated with the observations of Chauhan *et al.* (2003) [37]. But in the infected pups, the value significantly increased ( $p<0.01$ ), in a study of parasitic infected rats Shalaby *et al.* (2003) [38] noted elevated levels of serum creatinine in them and opined parasitisation induces the increase of creatinine levels in blood and also might be due to moderate to severe nephritis or toxic nephrosis.

**Table 4:** Eggs per gram and Percent Efficacy in pups before and after treatment

Group	Eggs Per Gram					Percent Efficacy (%)
	Pre-treatment	Days of observation post-treatment				
	0 <sup>th</sup> Day	3 <sup>rd</sup> Day	7 <sup>th</sup> Day	15 <sup>th</sup> Day	30 <sup>th</sup> Day	
I	0	0	0	0	0	
II	1200.00±57.73 <sup>a</sup> <sub>y</sub>	1316.66±47.72 <sup>a</sup> <sub>xy</sub>	1450.00±61.91 <sup>a</sup> <sub>wx</sub>	1533.33±49.44 <sup>a</sup> <sub>wx</sub>	1666.67±55.77 <sup>a</sup> <sub>w</sub>	
III	1216.66±60.09 <sup>a</sup> <sub>w</sub>	200.00±25.81 <sup>b</sup> <sub>x</sub>	150.00±22.36 <sup>b</sup> <sub>xy</sub>	33.33±21.08 <sup>b</sup> <sub>yz</sub>	0±0 <sup>b</sup> <sub>z</sub>	89.49
IV	1266.67±42.10 <sup>a</sup> <sub>w</sub>	166.66±21.08 <sup>b</sup> <sub>x</sub>	83.33±30.73 <sup>b</sup> <sub>xy</sub>	16.66±16.66 <sup>b</sup> <sub>y</sub>	0±0 <sup>b</sup> <sub>y</sub>	92.98
V	1300.00±36.51 <sup>a</sup> <sub>w</sub>	133.33±21.08 <sup>b</sup> <sub>x</sub>	50.00±22.36 <sup>b</sup> <sub>xy</sub>	0±0 <sup>b</sup> <sub>y</sub>	0±0 <sup>b</sup> <sub>y</sub>	95.29

Mean bearing different superscripts (a, b, c, d and e) in a column differ significantly ( $p<0.01$ ).

Mean bearing different subscripts (w, x, y and z) in a row differ significantly ( $p<0.01$ ).

The table shows that, the overall efficacy of Pyrantal pamoate was 89.49%. Sharma *et al.* (2006) [30] reported 80-100% efficacy using a combination of Pyrantel pamoate, Fenbendazole and Praziquantel against toxocarosis. Group 4 puppies, which were treated with Albendazole showed overall percent efficacy of 92.98%. Similar efficacy ranging from 80-100% was reported by Tiwari (1994) [39] against *Toxocara canis* infection in dogs. Group 5 puppies, who were treated with Pyrantel embonate, Oxantel embonate and Praziquantel showed 95.29% efficacy. The Pyrantel and Oxantel are the depolarizing neuromuscular blocking agents in nematode parasites and produces paralysis in them. Praziquantel initiates rapid muscular contraction by altering the ionic balance of muscle cell and causes spastic paralysis of the worms and are eliminated. Sinha *et al.* (2009) [40] used a product containing Pyrantel pamoate, Fenbendazole and Praziquantel against nematodiasis in dogs and found effective. Considering the clinical improvements, haemato-biochemical changes and therapeutic efficacies, these drugs were found effective in treatment of *Toxocara spp.* infection in pups.

#### 4. Conclusion

From the findings of the present study, the following conclusions were drawn: (i) The overall incidence of *Toxocara canis* infection in and around Kolkata city was 38.18%, (ii) the incidence rate was highest during the monsoon season (64.29%) and lowest in the winter season (9.52%), (iii) sex-wise prevalence rate was higher in the males (66.67%) than females (33.33%), (iv) incidence was higher (54.77%) in the age group of 1-3 months and lower (45.23%) in the age group of 4-6 months of age, (v) non-descript (local) breeds of puppies (61.90%) were most commonly infected than the pure breed puppies, (vi) a decrease of Hb, TEC, lymphocyte count, total serum protein, blood glucose, albumin, globulin ratio and increase in TLC, neutrophil, globulin, ALT, AST, total serum bilirubin, creatinine and eosinophil counts were noted in the pre-treatment infected groups of pups which changed in the post treatment observations, and (vii) all the three anthelmintics were found effective against the *Toxocara spp.* infection in the pups. However, for considering the best

#### 3.4 Therapeutic trail and Efficacy

The eggs per gram of faeces and percent efficacy in different groups have been presented in Table 4. The table shows that the healthy puppies of Group 1 did not reveal any ova throughout the experiment while the infected puppies in Group 2 showed gradual increase of the same. But with different treatments in Groups 3, 4, and 5, the EPG values declined gradually and became nil at the end of the experiment.

efficacy, the combination of Praziquantel, Pyrantel embonate and Oxantel embonate at a dose rate of 1 tab/10 kg b.wt. as single dose can suitably be recommended for treatment of toxocarosis in pups.

#### 5. Acknowledgements

The authors would like to acknowledge In-charge, Dog ward under Teaching Veterinary Clinical Complex (TVCC), Department of Veterinary Parasitology and Department of Biochemistry, Faculty of Veterinary and Animal Sciences under West Bengal University of Animal and Fishery Sciences, Kolkata, India for facilities and resources as well as necessary permissions to carry out the study.

#### 6. References

- Bassett J, Thomas J. McCurnin's Clinical Textbook for Veterinary Technicians. 8<sup>th</sup> Edn. St. Louis, MO: Elsevier; c2014.
- Chen J, Zhou DH, Nisbet AJ, Xu MJ, Huang SY, Li MW, *et al.* Advances in molecular identification, taxonomy, genetic variation and diagnosis of *Toxocara spp.* Infect Genet Evol. 2012;12(7):1344-8.
- Rostami A, Riahi SM, Hofmann A, Ma G, Wang T, Behniafar H, *et al.* Global prevalence of *Toxocara* infection in dogs. Adv. Parasitol. 2020;109:561-583.
- Mondal M, Basak DK. Studies on haematological and biochemical changes in piglets experimentally infected with embryonated *Toxocara canis* (Werner, 1782) ova. Journal of Interacademia. 2001;5(1): 81-86.
- Centre for Disease Control. Toxocarosis FAQs [Internet]. Global Health, Division of Parasitic Diseases and Malaria: 2020 Sep 5 [accessed: 2022 Feb 5]. Available from: [https://www.cdc.gov/parasites/toxocarosis/gen\\_info/faqs.html](https://www.cdc.gov/parasites/toxocarosis/gen_info/faqs.html)
- Eslahi AV, Badri M, Khorshidi A, Majidiani H, Hooshmand E, Hosseini H, *et al.* Prevalence of *Toxocara* and *Toxascaris* infection among human and animals in Iran with meta-analysis approach. BMC Infect Dis. 2020;20(1):20.
- Minnaar WN, Krecek RC, Fourie LJ. Helminths in dogs

- from a peri-urban resource-limited community in Free State Province, South Africa. *Vet. Parasitol.* 2002;107:343-349.
8. Oliveira-Sequeira TC, Amarante AF, Ferrari TB, Nunes LC. Prevalence of intestinal parasites in dogs from São Paulo State. Brazil. *Vet. Parasitol.* 2002;103:19-27.
  9. Habluetzel A, Traldi G, Ruggieri S, Attili AR, Scuppa P, Marchetti R, *et al.* An estimation of *Toxocara canis* prevalence in dogs, environmental egg contamination and risk of human infection in the Marche region of Italy. *Vet. Parasitol.* 2003;113:243-252.
  10. Rubel D, Zunino G, Santillán G, Wisnivesky C. Epidemiology of *Toxocara canis* in the dog population from two areas of different socioeconomic status, Greater Buenos Aires, Argentina. *Vet. Parasitol.* 2003;115:275-286.
  11. Wang CR, Qiu JH, Zhao JP, Xu LM, Yu WC, Zhu XQ. Prevalence of helminthes in adult dogs in Heilongjiang Province, the People's Republic of China. *Parasitol. Res.* 2006;99:627-630.
  12. Dai RS, Li ZY, Li F, Liu DX, Liu W, Liu GH, *et al.* Severe infection of adult dogs with helminths in Hunan Province, China poses significant public health concerns. *Vet. Parasitol.* 2009;160:348-350.
  13. Bhangale GN, Narladkar BW, Tayde RS. Systematic review and meta-analysis on the risk potential of zoonotic toxocariasis from soil contamination of public places in India. *Vet Parasitol Reg Stud Reports.* 2021;24:100560.
  14. Ahmad N, Maqbool A, Saeed K, Ashraf K, Qamar MF. Toxocariasis, its zoonotic importance and chemotherapy in dogs. *The J Anim. Plant Sci.* 2011;21:142-45.
  15. Shulaw WP, Diplomate. What do fecal worm egg counts tell us? Ohio State University, Fact sheet, Veterinary Preventive Medicine; c2011.
  16. Rao SS, Suryanarayana C. Clinico-biochemical and therapeutic studies on toxocariasis in dogs. *Indian Veterinary Journal.* 1995;72:1076-79.
  17. Soulsby E JL. Helminths, Arthropods and Protozoa of Domesticated Animals, 7<sup>th</sup> Edn. Bailliere, Tindall, London; c1982. p. 150-155.
  18. Schalm OW, Jain NC, Carroll EJ. *Veterinary Haematology*, 3<sup>rd</sup> Edn. Lea and Febiger, Philadelphia; c1975. p. 40.
  19. Koller A. Proteins. In: *Clinical Chemistry - Theory, Analysis and Correlation*, Kaplan LA and Pesce AJ (Eds.). Mosby, Toronto, Canada; c1984. p. 1268-1327.
  20. Corcoran RM, Durran SM. Albumin determination by a modified bromocresol method. *Clin Chem.* 1977;23:765.
  21. Tietz, N.W. *Clinical Guide to Laboratory Test.* W.B. Saunders Co., Philadelphia, USA; c1976. p. 238.
  22. Reitman S, Frankel S. A colorimetric method for the determination of serum glutamic Oxalacetic and glutamic pyruvic transaminases. *Am. J Clin. Pathol.* 1957;28:56-63.
  23. Malloy HT, Evelyn KA. The determination of bilirubin with the photoelectric colorimeter. *J Biol. Chem.* 1937;119:481-90.
  24. Toro G, Ackermann PG. *Practical clinical chemistry.* Boston, Little Brown and Co; c1975, p. 154.
  25. Soulsby, E JL. How parasites tolerate their host. *Br. Vet. J.* 1994;150:311-312.
  26. Snedecor GW, Cochran WG. *Statistical Methods.* Iowa State University Press, Ames, IA; c1976.
  27. Negrea O. Incidence of the main gastrointestinal and respiratory parasites in dogs from rural areas. *Clujul Medical Veterinar.* 2005;8: 23-25.
  28. Chattha MA, Aslam A, Rehman ZU, Khan JA, Avais M. Prevalence of *Toxocara canis* infection in dogs and its effects on various blood parameters in Lahore (Pakistan). *J Anim. Plant Sci.* 2009;19(2): 71-73.
  29. Deger YA, Gul A, Bildik S, Dede F, Yur F, Deger S. Alterations on some blood parameters and vitamin C levels in infected dogs with parasites. *Journal of Turkish Parasitology*, 1997;21(2):195-198.
  30. Sharma SK, Singha SRP, Sinha S, Mahtha RK. Gastrointestinal helminthic parasites and treatment in different breeds of dogs. *Indian Vet J.* 2006;83:834-836.
  31. Chatterjee A K. Haemato biochemical, Histopathological studies on *A. caninum* in pups with special reference to the efficacy of certain anthelmintics. M.V.Sc. thesis. BCKVV, West Bengal; c1993.
  32. Ogunkoya AB, Useh NM, Esievo KAN. The haemograms of dogs with Gastrointestinal Parasites in Zaria, Nigeria. *J Anim Vet. Adv.* 2006;5(9):782-785.
  33. Sharma SK, Sinha SRP, Sinha S, Jayachandran C, Kumar M. Post-treatment haematological studies on toxocariasis in dogs. *Indian Journal of Parasitology.* 2010;24(1):63-65
  34. Devi AR, Pradhan NR, Bandyopadhyay S. Haemato-biochemical changes in experimentally induced ancylostomiasis in dogs. *Indian J Vet Med.* 2011;29(2):32-33.
  35. Coles EH. *Vety. Clinical pathology*, 4<sup>th</sup> Edn., W.B. Saunders Company Philadelphia, West Washington Square; c1986.
  36. Brar NS, Naurial DC. Haematological, biochemical and chemical profile of experimentally induced anaemic dogs. *Indian J Vet Med.* 1986;13:52-54.
  37. Chauhan RS, Chandra D. *Veterinary Laboratory Diagnosis.* 1st Edition, International Book Distributing Co. Lucknow, U.P. India; c2003.
  38. Shalaby SI, Hassan NR, Raafat A, Anter OM, El-Mahdy M, Mohamed IB, Gupta N. Effect of parasitization by certain heterophyid species in rats and dogs in Egypt. *Biol Memoirs.* 2003;29(1):21-29.
  39. Tiwari SP. Management of natural cases of *Ancylostoma caninum* and *Toxocara canis* in pedigree dogs with albendazole. *Vet Jour.* 1994;4:115-117.
  40. Sinha SRP, Sharma SK, Sinha S, Kumar P, Kumari S, Sinha VK. Management of dogs suffering from chronic mixed infection of nematodes. *Indian J Vet Med.* 2009;29(1):45-46.